Processa Pharmaceuticals (PCSA) EBIT (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly EBIT came in at -$3.3 million in Q1 2026, down 17.01% YoY from -$4.0 million in Q1 2025, and up 10.01% on a QoQ basis from -$3.7 million in Q4 2025.
Processa Pharmaceuticals (PCSA) EBIT (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of EBIT data on file, last reported at -$3.3 million in Q1 2026.
- Quarterly EBIT fell 17.01% year-over-year to -$3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.5 million (down 19.72% YoY) and the FY2025 annual result came in at -$14.0 million, down 16.08% from the prior year.
- EBIT improved to -$3.3 million in Q1 2026, from -$3.7 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$2.2 million in Q3 2023 to a low of -$13.1 million in Q4 2022.
- A 5-year average of -$4.0 million and a median of -$3.3 million in 2026 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT sank 287.88% — and 2023, when it surged 81.1%.
- Tracing PCSA's EBIT over 5 years: stood at -$13.1 million in 2022, then surged by 81.1% to -$2.5 million in 2023, then fell by 10.74% to -$2.7 million in 2024, then plunged by 35.37% to -$3.7 million in 2025, then rose by 10.01% to -$3.3 million in 2026.
- The last three EBIT figures came in at -$3.3 million (Q1 2026), -$3.7 million (Q4 2025), and -$3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Processa Pharmaceuticals | 5.72 Mn | 5.72 Mn | - | -2.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.33 Mn |
| Dec 31, 2025 | -3.70 Mn |
| Sep 30, 2025 | -3.49 Mn |
| Jun 30, 2025 | -3.95 Mn |
| Mar 31, 2025 | -2.85 Mn |
| Dec 31, 2024 | -2.73 Mn |
| Sep 30, 2024 | -3.42 Mn |
| Jun 30, 2024 | -3.08 Mn |
| Mar 31, 2024 | -2.81 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -2.17 Mn |
| Jun 30, 2023 | -2.71 Mn |
| Mar 31, 2023 | -4.11 Mn |
| Dec 31, 2022 | -13.07 Mn |
| Sep 30, 2022 | -6.06 Mn |
| Jun 30, 2022 | -5.17 Mn |
| Mar 31, 2022 | -3.23 Mn |
| Dec 31, 2021 | -3.37 Mn |
| Sep 30, 2021 | -3.11 Mn |
| Jun 30, 2021 | -3.46 Mn |